Clinical characteristics and risk factors of Staphylococcus aureus bloodstream infection in a tertiary-care hospital in China: a single-center retrospective 11-year study

中国某三级医院金黄色葡萄球菌血流感染的临床特征及危险因素:一项单中心回顾性11年研究

阅读:1

Abstract

BACKGROUND: Staphylococcus aureus (SA) is one of the most important pathogens of bloodstream infection (BSI). Because of its high morbidity and mortality, Staphylococcus aureus bloodstream infection (SA-BSI) poses a serious threat to public health. We sought to analyze the clinical characteristics, drug resistance and risk factors of poor prognosis in patients with SA-BSI. METHODS: The clinical data of 430 patients with SA-BSI in the First Affiliated Hospital of Bengbu Medical University from January 2013 to October 2024 were analyzed retrospectively. Univariate and multivariate logistic regression analysis was used to analyze the risk factors of poor prognosis. RESULTS: Among the 430 cases of SA-BSI, the isolation rate of MRSA was 50.47% (217/430) and the incidence of poor prognosis was 18.14% (78/430). The rates of admission to ICU, respiratory failure, central venous catheterization, endotracheal intubation, urinary catheter, tracheotomy and non-invasive mechanical ventilation in MRSA group were significantly higher than those in MSSA group (p < 0.05). Respiratory failure (OR = 6.565, 95%Cl: 1.275 ~ 33.803, p = 0.024), septic shock (OR = 7.185, 95%Cl: 1.15 ~ 44.874, p = 0.035), high Pitt bacteremia score (OR = 2.156, 95%Cl: 1.752 ~ 2.653, p < 0.001) and high serum procalcitonin level (OR = 1.064, 95%Cl: 1.025 ~ 1.104, p = 0.001) were independent risk factors for poor prognosis in patients with SA-BSI. CONCLUSION: Patients with respiratory failure, ICU admission, or indwelling catheters are at increased risk for MRSA bloodstream infection, while respiratory failure, septic shock, high Pitt bacteremia score, and elevated procalcitonin may worsen prognosis of patients with SA-BSI. To improve outcomes, clinicians should implement targeted interventions, including enhanced screening and contact precautions for high-risk patients, judicious management of invasive devices, and antimicrobial stewardship with early source control. Strengthening risk assessment and these measures can optimize SA-BSI management and patient prognosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。